The ophthalmology community celebrates a monumental achievement that promises to reshape treatment approaches for one of retinal medicine’s most perplexing disorders. Patients diagnosed with macular telangiectasia type 2 now have access to an innovative therapeutic solution that represents the first successful intervention specifically designed to combat this progressive condition. The MacTel Challenge: Decades of Limited Read.